Baird Financial Group Inc. Trims Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Baird Financial Group Inc. reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.5% during the 4th quarter, HoldingsChannel reports. The firm owned 7,181 shares of the medical instruments supplier’s stock after selling 338 shares during the period. Baird Financial Group Inc.’s holdings in LeMaitre Vascular were worth $662,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its holdings in LeMaitre Vascular by 48.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock worth $1,227,000 after purchasing an additional 4,330 shares during the period. Invesco Ltd. increased its holdings in shares of LeMaitre Vascular by 50.5% in the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock valued at $16,124,000 after acquiring an additional 58,720 shares during the period. Barclays PLC increased its holdings in shares of LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after acquiring an additional 29,180 shares during the period. Compass Planning Associates Inc purchased a new position in shares of LeMaitre Vascular in the 4th quarter valued at $567,000. Finally, Teacher Retirement System of Texas increased its holdings in shares of LeMaitre Vascular by 31.8% in the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier’s stock valued at $9,385,000 after acquiring an additional 24,586 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. The trade was a 26.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $83.00 on Thursday. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The stock’s fifty day moving average price is $84.07 and its 200 day moving average price is $93.05. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 45.36, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $59.87 million for the quarter, compared to analysts’ expectations of $57.61 million. During the same quarter last year, the firm earned $0.44 earnings per share. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date is Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.96%. LeMaitre Vascular’s dividend payout ratio (DPR) is 40.40%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on LMAT shares. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.14.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.